Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CABOZANTINIB S-MALATE for Soft tissue sarcoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 192 adverse event reports in the FDA FAERS database where CABOZANTINIB S-MALATE was used for Soft tissue sarcoma.

Most Reported Side Effects for CABOZANTINIB S-MALATE

Side Effect Reports % Deaths Hosp.
Diarrhoea 8,282 21.1% 315 1,313
Fatigue 6,819 17.4% 261 897
Off label use 5,245 13.4% 591 633
Nausea 4,341 11.1% 175 736
Decreased appetite 4,076 10.4% 233 751
Blood pressure increased 2,939 7.5% 63 416
Malignant neoplasm progression 2,718 6.9% 909 626
Palmar-plantar erythrodysaesthesia syndrome 2,706 6.9% 119 349
Weight decreased 2,657 6.8% 139 462
Stomatitis 2,560 6.5% 91 347
Death 2,504 6.4% 2,497 368
Constipation 2,098 5.3% 91 359
Blister 1,943 5.0% 27 150
Vomiting 1,870 4.8% 113 491
Taste disorder 1,851 4.7% 43 236

Other Indications for CABOZANTINIB S-MALATE

Renal cancer (15,186) Renal cell carcinoma (9,156) Product used for unknown indication (3,104) Hepatocellular carcinoma (2,670) Thyroid cancer (1,615) Metastatic renal cell carcinoma (1,055) Metastases to lung (727) Clear cell renal cell carcinoma (704) Metastases to bone (514) Hepatic cancer (508)

Other Drugs Used for Soft tissue sarcoma

PAZOPANIB (1,400) DOXORUBICIN (302) TAZEMETOSTAT HYDROBROMIDE (298) IFOSFAMIDE (237) TRABECTEDIN (183) NIVOLUMAB (156) OLARATUMAB (156) IMATINIB (124) SUNITINIB MALATE (123) RIPRETINIB (110)

Related Pages

CABOZANTINIB S-MALATE Full Profile All Soft tissue sarcoma Drugs CABOZANTINIB S-MALATE Demographics CABOZANTINIB S-MALATE Timeline